
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="center" style="font-size: 14pt"><B>SECURITIES AND EXCHANGE COMMISSION</B>

<DIV align="center" style="font-size: 12pt"><B>WASHINGTON, D.C. 20549</B>
</DIV>


<P>
<HR noshade width="26%" align="center" size="1">
<P>




<P align="center" style="font-size: 18pt">FORM 8-K



<P>
<HR noshade width="26%" align="center" size="1">
<P>




<P align="center" style="font-size: 12pt">CURRENT REPORT<BR>
PURSUANT TO SECTION 13 OR 15(d) OF<BR>
THE SECURITIES EXCHANGE ACT OF 1934



<P>
<HR noshade width="26%" align="center" size="1">
<P>




<P align="center" style="font-size: 10pt">DATE OF REPORT (DATE OF
EARLIEST EVENT REPORTED) DECEMBER&nbsp;27, 2004



<P>
<HR noshade width="26%" align="center" size="1">
<P>



<P align="center" style="font-size: 24pt"><B>NORTHWEST BIOTHERAPEUTICS, INC.</B>

<DIV align="center" style="font-size: 10pt">(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)</DIV>



<P>
<HR noshade width="26%" align="center" size="1">
<P>



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="33%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="26%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">DELAWARE</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">(STATE OR OTHER
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">0-33393
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">94-3306718</TD>
</TR>

<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">JURISDICTION
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(COMMISSION FILE
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(I.R.S. EMPLOYER</TD>
</TR>

<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">OF INCORPORATION)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">NUMBER)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">IDENTIFICATION NO.)</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">22322 20th Avenue SE, Suite&nbsp;150, Bothell, WA 98021<BR>
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)



<P>
<HR noshade width="26%" align="center" size="1">
<P>




<P align="center" style="font-size: 10pt">REGISTRANT&#146;S TELEPHONE NUMBER, INCLUDING AREA CODE (425)&nbsp;608-3000
&nbsp;&nbsp;&nbsp;

<P>
<HR noshade width="26%" align="center" size="1">
<P>

<P align="center" style="font-size: 10pt">INAPPLICABLE<BR>
(FORMER NAME OR FORMER ADDRESS IF CHANGED SINCE LAST REPORT)



<P>
<HR noshade width="26%" align="center" size="1">
<P>




<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form&nbsp;8-K is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:



<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#091;&nbsp;&nbsp;&#093; Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#091;&nbsp;&nbsp;&#093; Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#091;&nbsp;&nbsp;&#093; Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#091;&nbsp;&nbsp;&#093; Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR>


</TABLE>

<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<P><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>


<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD colspan="9"><A HREF="#000">ITEM 1.01 Entry Into a Material Definitive Agreement</A></TD></TR>
<TR><TD colspan="9"><A HREF="#001">Item&nbsp;9.01 Financial Statements and Exhibits</A></TD></TR>
<TR><TD colspan="9"><A HREF="#002">SIGNATURE</A></TD></TR>
<TR><TD colspan="9"><A HREF="v04302exv10w1.txt">EXHIBIT 10.1</A></TD></TR>
<TR><TD colspan="9"><A HREF="v04302exv10w2.txt">EXHIBIT 10.2</A></TD></TR>
<TR><TD colspan="9"><A HREF="v04302exv10w3.txt">EXHIBIT 10.3</A></TD></TR>
<TR><TD colspan="9"><A HREF="v04302exv10w4.txt">EXHIBIT 10.4</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>




<!-- link1 "ITEM 1.01 Entry Into a Material Definitive Agreement" -->
<DIV align="left"><A NAME="000"></A></DIV>

<P align="left" style="font-size: 10pt"><B>ITEM 1.01 Entry Into a Material Definitive Agreement.</B>


<P align="left" style="font-size: 10pt">Northwest Biotherapeutics, Inc. (the &#147;Company&#148;) announced today that, on
December&nbsp;27, 2004, it received a $250,000 loan from Toucan Capital Fund II,
L.P. (&#147;Toucan&#148;). The loan accrues interest at 10% per year, matures on
December&nbsp;27, 2005, and the principal and interest is convertible into capital
stock of the Company, generally at Toucan&#146;s option, prior to repayment. The
principal and interest on the loan is currently convertible at $0.04 per share
(subject to adjustment). In connection with this new loan, the Company has
issued a warrant to Toucan, which is exercisable for up to 2.5&nbsp;million shares
of the Company&#146;s capital stock. The exercise price of the warrant is the
lesser of (i) $.10 per share (subject to certain adjustments); or (ii)&nbsp;a 35%
discount to the average closing price of the Company&#146;s common stock during the
twenty trading days prior to the first closing of the sale of convertible
preferred stock of the Company, but not less than $.04 per share. The Company
believes that the additional $250,000 received from Toucan on December&nbsp;27, 2004
will be sufficient to satisfy its cash requirements until January&nbsp;8, 2005.



<P align="left" style="font-size: 10pt">To date, the Company has issued eight promissory notes to Toucan pursuant to
which Toucan has loaned the Company an aggregate of $4.35&nbsp;million. In
connection with the issuance of promissory notes to Toucan, the Company has
issued and Toucan has received warrants that are currently exercisable for an
aggregate of up to 98.5&nbsp;million shares of the Company&#146;s capital stock.



<P align="left" style="font-size: 10pt">In connection with the recent loan from Toucan, the Company and Toucan agreed
to amend the Amended and Restated Recapitalization Agreement, dated as of July
30, 2004, amended on October&nbsp;22, 2004 and on November&nbsp;10, 2004, between the
parties (&#147;Amendment No.&nbsp;3&#148;). Amendment No.&nbsp;3 extends the bridge period which
previously expired on December&nbsp;17, 2004 through January&nbsp;8, 2005 and removes a
covenant to which the Company was previously subject. During the bridge period
the Company generally is prohibited from entering into discussions with any
third party regarding a sale of the Company, its assets or the issuance of its
securities.



<P align="left" style="font-size: 10pt">Also in connection with the recent loan from Toucan, the Company and Toucan
agreed to amend the Amended and Restated Binding Term Sheet dated April&nbsp;26,
2004, and amended and restated on October&nbsp;26, 2004 between the parties (the
&#147;Term Sheet&#148;). The Term Sheet, as amended, reduced warrant coverage in the
potential private placement by $250,000 and removed a closing condition.



<P align="left" style="font-size: 10pt">The Amended and Restated Recapitalization Agreement, as amended, contemplates a
proposed equity financing that would provide for the potential issuance and
sale of up to $40&nbsp;million of convertible preferred stock (including any shares
issuable upon conversion of bridge funding, but not including any shares
issuable upon exercise of warrants, options, and similar instruments or
obligations), in one or more closings over a period of 12&nbsp;months from the first
closing of the sale of convertible preferred stock. If issued, the convertible
preferred stock will be issued at a price per share equal to the lesser of
$0.10 (as adjusted for stock splits, stock dividends and the like) or a 35%
discount to the average closing price of the Company&#146;s common stock during the
twenty trading days prior to the first closing of the proposed equity
financing, but not less than $0.04 per share. The proposed equity financing is
contingent upon the Company complying with covenants in the Amended and
Restated Recapitalization Agreement, as amended, and locating investors who are
willing to invest in the Company on the terms proposed.



<P align="left" style="font-size: 10pt">The foregoing description of Amendment No.&nbsp;3, the note, the warrant and the
Term Sheet, all of which are filed as exhibits to the Form&nbsp;8-K, are qualified
in their entirety by reference to the full text of the agreements.



<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<!-- link1 "Item&nbsp;9.01 Financial Statements and Exhibits" -->
<DIV align="left"><A NAME="001"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;9.01 Financial Statements and Exhibits</B>


<P align="left" style="font-size: 10pt">(c)&nbsp;Exhibits.



<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right">10.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Amendment No.&nbsp;3 to the Amended and Restated Recapitalization Agreement
between Northwest Biotherapeutics, Inc. and Toucan Capital Fund II, L.P.,
dated December&nbsp;27, 2004.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right">10.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Loan Agreement, Security Agreement and 10% Convertible, Secured Promissory
Note in the principal amount of $250,000 between Northwest Biotherapeutics,
Inc. and Toucan Capital Fund II, L.P. dated December&nbsp;27, 2004.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right">10.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Warrant to purchase securities of the Company dated December&nbsp;27, 2004 issued
to Toucan Capital Fund II, L.P.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right">10.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Amendment to Amended and Restated Binding Term Sheet dated December&nbsp;27, 2004.</TD>
</TR>

</TABLE>

<!-- link1 "SIGNATURE" -->
<DIV align="left"><A NAME="002"></A></DIV>

<P align="center" style="font-size: 10pt">SIGNATURE


<P align="left" style="font-size: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="44%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="46%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left">NORTHWEST BIOTHERAPEUTICS, INC.</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/&nbsp;Alton Boynton</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Alton L. Boynton</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="left" style="font-size: 10pt">December&nbsp;30, 2004.




<P align="center" style="font-size: 10pt">&nbsp;
</DIV>


</BODY>
</HTML>

